Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that transverse tissue barriers to selectively target activated cells only in regions of inflammation. Ashvattha's targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation.